Page last updated: 2024-08-17

carbostyril and Depressive Disorder, Major

carbostyril has been researched along with Depressive Disorder, Major in 151 studies

Research

Studies (151)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's39 (25.83)29.6817
2010's103 (68.21)24.3611
2020's9 (5.96)2.80

Authors

AuthorsStudies
Furukawa, Y; Hamza, T; Kasai, K; Obata, S; Oguro, S; Ostinelli, EG1
Boucher, M; de Jong-Laird, A; Katzman, MA; MacKenzie, EM; Therrien, F; Wang, F1
Carpenter, JS; Crouse, JJ; Garland, A; Hickie, IB; Koethe, D; Leweke, FM; McHugh, C; Nichles, A; Rohleder, C; Scott, EM; Song, YJC; Wilson, C; Zmicerevska, N1
Eriksson, H; Meehan, SR; Newcomer, JW; Weiss, C; Zhang, P1
Carroll, KJ; Koch, G; Lee, J; Ouyang, J; Zhang, P1
Antoun Reyad, A; Girgis, E; Mishriky, R1
Baker, RA; Krystal, AD; Lindsten, A; Mittoux, A1
Mishra, VC; Swami, MK1
Futamura, T; Hirose, T; Kikuchi, T; Maeda, K; McQuade, RD; Suzuki, M1
Edinoff, AN; Girma, B; Kaye, AD; Kaye, AJ; Kaye, AM; Kaye, JS; Leethy, KN; Maxey, BS; Mychaskiw, G; Odisho, A; Ren, AL; Urits, I; Viswanath, O; Wu, NW1
Aftab, A; Gao, K1
Dong, C; Fujita, Y; Futamura, T; Hashimoto, K; Ma, M; Ohgi, Y; Ren, Q; Yang, C1
Higashi, K; Ishigooka, J; Iwashita, S; Liew, EL; Tadori, Y1
Hobart, M; Nelson, JC; Weiller, E; Weiss, C; Zhang, P1
Augustine, C; Carroll, K; Hobart, M; Koch, G; Zhang, P1
Augustine, C; Brewer, C; Hefting, N; Hobart, M; Josiassen, MK; McQuade, RD; Sanchez, R; Skuban, A; Zhang, P1
Aladeen, T; Capote, H; Lee, Y; McIntyre, RS; Rainka, M; Rong, C; Westphal, E1
Burudpakdee, C; Greene, M; Hartry, A; Seetasith, A1
Augustine, C; Brewer, C; Hefting, N; Hobart, M; McQuade, RD; Sanchez, R; Skuban, A; Zhang, P1
Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P1
Hefting, N; Hobart, M; Lepola, U; Zhang, D1
Bauer, M; Hefting, N; Hobart, M; Josiassen, MK; Lindsten, A1
Eriksson, H; Hobart, M; Meehan, SR; Weiss, C; Zhang, P1
Broder, MS; Chang, E; Greene, M; Hartry, A; Yan, T; Yermilov, I1
Brown, ES; Escalante, C; Holmes, T; Ivleva, E; Khaleghi, N; Mason, BL; Nakamura, A; Van Enkevort, E1
Citrome, LL; Manning, JS; McIntosh, D; McIntyre, RS1
Iwata, N; Kishi, T; Matsuda, Y; Mishima, K; Nomura, I; Sakuma, K1
Begley, AE; Blumberger, D; Butters, M; Dew, MA; Joel, I; Lenze, EJ; Mazumdar, S; Mulsant, BH; Reynolds, CF1
Cassiello, C; Dording, C; Fava, M; King, F; Mischoulon, D; Pencina, M1
Cho, SJ; Choi, JH; Hahn, SW; Han, C; Jeon, HJ; Jon, DI; Jun, TY; Kim, SG; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Park, EJ; Seo, HJ1
Higuchi, T; Ishigooka, J; Kamijima, K; Kanba, S; Kinoshita, T; Koyama, T; Ohmori, T; Ozaki, N1
Han, C; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Wang, SM1
Han, C; Jeon, HJ; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Seo, HJ; Wang, SM1
Chibnall, JT; Conway, CR; Cornell, ME; Cumming, P; Gangwani, S; Gebara, MA; McConathy, JE; Mintun, MA; Perantie, DC; Price, JL; Sheline, YI1
Begley, A; Butters, MA; Koenig, AM; Ogbagaber, S; Reynolds, CF; Wahed, AS1
Baker, RA; Berman, RM; Eudicone, JM; Laubmeier, KK; Marcus, RN; McQuade, RD; Nelson, JC; Rahman, Z; Sheehan, JJ1
Berman, RM; Hatch, A; Largay, K; Marler, SV; Nelson, JC; Sheehan, JJ; Stewart, TD1
Hu, JY; Huang, A; Liu, YY; Liu, ZL; Wang, LM; Wen, XJ1
Philip, NS1
Higuchi, T; Kamijima, K; Kato, M; Ono, H; Otsubo, T; Ozaki, N1
Makkos, Z1
Baker, RA; Berman, RM; Cain, ZJ; Clayton, AH; Forbes, RA; Marcus, R; Marler, SV; Sheehan, JJ; Thase, ME1
Sharma, V; Sommerdyk, C; Xie, B1
Baker, RA; Dunlop, BW; Eudicone, JM; McCabe, B; Sheehan, JJ1
Chiou, CC; Lane, HY; Lin, CY; Tsai, GE; Wang, HS; Wu, VY; Wu, YH1
Howland, RH1
Huh, L; Lee, BJ1
Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R1
Citrome, L4
Augustine, C; Carson, WH; Eriksson, H; Hobart, M; McQuade, RD; Nyilas, M; Sanchez, R; Skuban, A; Thase, ME; Youakim, JM; Zhang, P1
Carson, WH; Eriksson, H; Hobart, M; McQuade, RD; Nyilas, M; Sanchez, R; Skuban, A; Thase, ME; Youakim, JM; Zhang, P1
McKeage, K1
Stahl, SM1
McIntyre, RS; Weiller, E; Weiss, C; Zhang, P1
Bruijnzeel, D; Tandon, R1
Baker, RA; Ota, A; Perry, P; Sheehan, DV; Tsuneyoshi, K; Weiller, E; Weisler, RH1
Baker, RA; Davidsen, CK; Fava, M; Ménard, F1
Aigbogun, MS; Duffy, R; Hartry, A; Kamat, SA; Legacy, S; Sussman, M; Yu, J1
Baker, RA; Davis, LL; Ota, A; Perry, P; Tsuneyoshi, K; Weiller, E1
Baker, RA; Fava, M; Matsushima, Y; Okame, T; Perry, P; Weiller, E1
Beyer, JL; Weisler, RH1
Baker, RA; Krystal, AD; Meisels, P; Mittoux, A1
Han, C; Jeon, SW; Ko, YH; Masand, PS; Pae, CU; Patkar, AA; Yoon, S1
Dong, C; Futamura, T; Hashimoto, K; Ma, M; Ohgi, Y; Ren, Q; Yang, C; Yao, W; Zhang, JC1
Fava, M; Weiller, E; Weiss, C; Zhang, P1
Gallipani, A; Markovic, M; Maroney, M; Patel, KH1
Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR; Zervas, IM1
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B1
Lyseng-Williamson, KA; Scott, LJ; Weber, J1
Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K1
Khan, A1
Ammerman, DK; Coley, KC; Fabian, TJ; Ganguli, R; Kim, E; Kim, MS; Saul, MI; Scipio, TM; Whitehead, R1
Mathew, SJ1
Denninger, JW; Dording, C; Fava, M; Hilliker, S; Homberger, C; Matthews, JD; Park, L; Rooney, K; Siefert, C; Sklarsky, K; van Nieuwenhuizen, AO1
Carroll, BJ1
Tsai, AC1
Kyomen, HH; Whitfield, TH1
Berman, RM; Carlson, BX; Fava, M; Marcus, RN; Nelson, CJ; Pikalov, A; Qi, Y; Thase, ME; Tran, QV; Trivedi, MH; Yang, H1
Butters, MA; Dew, MA; Driscoll, HC; Lenze, EJ; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Sheffrin, M1
Corey-Lisle, PK; Guo, Z; Kim, E; Lennox, RD; Pikalov, A; Trivedi, MH1
Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM1
Adson, D; Berman, RM; Carson, WH; Fava, M; Hazel, J; Marcus, RN; McQuade, RD; Swanink, R; Taylor, L; Thase, ME; Trivedi, MH1
Preskorn, SH1
Baker, RA; Berman, RM; Fava, M; Marcus, RN; Pikalov, A; Thase, ME; Tran, QV; Wisniewski, SR; Yang, H1
Baker, RA; Berman, RM; Carlson, BX; Eudicone, JM; Mankoski, R; Nelson, JC; Pikalov, A; Tran, QV1
Pae, CU1
Carlson, BX; Chen, CC; Guo, Z; Kan, HJ; Kim, E; Pikalov, A; Tran, QV; Wisniewski, SR1
Ansseau, M; Pitchot, W1
Radics, J1
Lai, CH3
Kitamura, H; Someya, T; Yokoyama, Y1
Berman, RM; Carlson, BX; Eudicone, JM; Marchant, BK; Marcus, RN; Martin, ML; Pikalov, A; Reimherr, FW; Tran, QV1
Tényi, T; Vörös, V1
Berman, RM; Carlson, BX; Eudicone, JM; Khan, A; Pikalov, A; Tran, QV; Trivedi, MH; Weisler, RH; Yang, H1
Andersson, C; Berman, RM; Carlson, BX; Eudicone, JM; Forbes, RA; Nelson, JC; Steffens, DC; Tran, QV; Yang, H1
Chen, J; Gao, K; Kemp, DE1
Guerdjikova, A; Keck, PE; McElroy, SL; Mori, N1
Chang, CH; Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW1
Ramaswamy, S; Selvaraj, V; Sharma, A; Wilson, D1
Depping, AM; Gaudchau, A; Kissling, W; Komossa, K; Leucht, S1
Leinonen, E; Valtonen, HM; Viikki, M1
Katzman, MA1
Blier, P; Blondeau, C1
Forbes, A; Pae, CU; Patkar, AA1
Leelahanaj, T1
Frost, M; Marcus, RM; McQuade, RD; Sanchez, R1
Fikretoglu, D; Liu, A; McIntosh, D; Richardson, JD1
Catapano, F; Esposito, G; Fabrazzo, M; Maj, M; Monteleone, P; Perris, F1
Bagalman, E; Carls, GS; Curkendall, SM; Forbes, RA; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME1
Jang, FL; Lin, CH; Lin, SH1
Fava, M; Hsieh, WH; Levy, M; Mischoulon, D; Papakostas, GI; Pencina, MJ; Pet, LR; Pollack, MH; Ward, S; Witte, J1
Dalton, ED; Dording, CM; Fava, M; Mischoulon, D; Pencina, MJ1
Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW1
Baker, RA; Berman, RM; Camacho, TA; Chambers, JS; Eudicone, JM; Forbes, RA; Muzina, DJ1
Tomba, E1
Bou Khalil, R; Dahdah, P; Kahn, DA; Richa, S1
Fava, M; Flynn, M; Harper, L; Iosifescu, D; Levy, M; Mischoulon, D; Pencina, M; Pollack, M; Rickels, K; Witte, J1
Baker, RA; Bellocchio, EE; Berman, RM; Eudicone, JM; Marcus, RN; McQuade, RD; Nelson, JC; Rollin, LM; Thase, ME1
Baker, RA; Forbes, RA; Jing, Y; Oster, G; Papakostas, GI; Taneja, C1
Lin, CC; Lin, HY; Liu, CC1
Cho, AR; Kang, WS; Park, JK1
Forbes, RA; Guo, Z; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME1
Choi, JE; Han, DH; Kim, SM; Min, KJ; Renshaw, PF1
Doros, G; Fava, M; Meisner, A; Pencina, M; Rybin, D1
Hellerstein, DJ1
Malik, AR; Ravasia, S1
Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA1
Baldessarini, RJ; Grant, MJ1
Nemeroff, CB; Simon, JS1
Alpert, JE; Burns, AM; Fava, M; Kinrys, G; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Worthington, JJ1
Sharma, A; Sorrell, JH1
Maytal, G; Ostacher, M; Stern, TA1
Jun, TY; Lee, C; Masand, PS; Pae, CU; Paik, IH; Patkar, AA1
Fiedler, U; Wolf, J1
Carroll, BT; Goforth, HW1
Baghai, TC; Born, C; Eser, D; Häfner, S; Hecht, S; Hermisson, I; Nothdurfter, C; Rupprecht, R; Schüle, C1
Berman, RM; Carson, WH; Corey-Lisle, PK; Khan, A; Marcus, RN; McQuade, RD; Swanink, R1
Burrows, G; Jefferys, D1
Arnold, KK; Yager, J1
Chou, YH; Su, TP; Yang, KC1
Papakostas, GI; Shelton, RC1
Bowden, CL; Carson, WH; Jonas, A; Khan, A; Marcus, RN; McQuade, RD; Owen, R; Thase, ME; Wu, X1
Chriki, LS; Dunn, RT; Filkowski, MM; Ghaemi, SN; Stan, VA1
Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH1

Reviews

31 review(s) available for carbostyril and Depressive Disorder, Major

ArticleYear
Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis.
    Psychiatry and clinical neurosciences, 2022, Volume: 76, Issue:9

    Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Quinolones; Randomized Controlled Trials as Topic; Reproducibility of Results; Thiophenes

2022
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
    International clinical psychopharmacology, 2020, Volume: 35, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome

2020
Discovery research and development history of the dopamine D
    Neuropsychopharmacology reports, 2021, Volume: 41, Issue:2

    Topics: Aripiprazole; Depressive Disorder, Major; Dopamine; Dopamine Agonists; Humans; Quinolones; Research; Thiophenes; United States

2021
Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
    Psychopharmacology bulletin, 2021, 03-16, Volume: 51, Issue:2

    Topics: Antipsychotic Agents; Depressive Disorder, Major; Humans; Quinolones; Schizophrenia; Thiophenes

2021
The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.
    Expert opinion on drug discovery, 2017, Volume: 12, Issue:10

    Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Quinolones; Thiophenes

2017
Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.
    The international journal of neuropsychopharmacology, 2019, 03-01, Volume: 22, Issue:3

    Topics: Antidepressive Agents; Depressive Disorder, Major; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Humans; Prospective Studies; Quinolones; Randomized Controlled Trials as Topic; Serotonin Agents; Single-Blind Method; Thiophenes

2019
Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
    The international journal of neuropsychopharmacology, 2019, 11-01, Volume: 22, Issue:11

    Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Outcome Assessment, Health Care; Quinolones; Randomized Controlled Trials as Topic; Serotonin Agents; Thiophenes

2019
Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2014, Volume: 47, Issue:7

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Depressive Disorder, Major; Dibenzothiazepines; Double-Blind Method; Drug Synergism; Humans; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Risperidone; Treatment Outcome; Young Adult

2014
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel
    International journal of clinical practice, 2015, Volume: 69, Issue:9

    Topics: Antidepressive Agents; Antipsychotic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes

2015
Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Drugs of today (Barcelona, Spain : 1998), 2015, Volume: 51, Issue:7

    Topics: Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptors, Dopamine D2; Schizophrenia; Thiophenes

2015
Brexpiprazole (Rexulti) for schizophrenia and depression.
    The Medical letter on drugs and therapeutics, 2015, Aug-17, Volume: 57, Issue:1475

    Topics: Animals; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Serotonin Agents; Thiophenes

2015
Adjunctive Brexpiprazole: A Review in Major Depressive Disorder.
    CNS drugs, 2016, Volume: 30, Issue:2

    Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Quinolones; Thiophenes

2016
Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Animals; Depressive Disorder, Major; Humans; Quinolones; Schizophrenia; Thiophenes

2016
Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:1

    Topics: Depressive Disorder, Major; Humans; Quinolones; Serotonin Agents; Thiophenes

2017
Brexpiprazole.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:4

    Topics: Antidepressive Agents; Antipsychotic Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Thiophenes; Weight Gain

2017
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
    L'Encephale, 2008, Volume: 34, Issue:2

    Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome

2008
Aripiprazole: in major depressive disorder.
    CNS drugs, 2008, Volume: 22, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Depressive Disorder, Major; Disability Evaluation; Drug Tolerance; Humans; Piperazines; Quinolones

2008
Current evidence for aripiprazole as augmentation therapy in major depressive disorder.
    Expert review of neurotherapeutics, 2008, Volume: 8, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Chemotherapy, Adjuvant; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Piperazines; Quinolones; Treatment Outcome

2008
Treatment-resistant depression: recent developments and future directions.
    Depression and anxiety, 2008, Volume: 25, Issue:12

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Combined Modality Therapy; Deep Brain Stimulation; Depressive Disorder, Major; Drug Resistance; Electroconvulsive Therapy; Humans; Piperazines; Prognosis; Quinolones; Tetrahydrofolates; Transcranial Magnetic Stimulation; Treatment Outcome; Vagus Nerve Stimulation

2008
Treatment options for the patient who does not respond well to initial antidepressant therapy.
    Journal of psychiatric practice, 2009, Volume: 15, Issue:3

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Drug Approval; Drug Resistance; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Piperazines; Psychotropic Drugs; Quinolones; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Vagus Nerve Stimulation

2009
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Biomarkers; Blood Glucose; Body Mass Index; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Lipids; Logistic Models; Male; Metabolic Diseases; Middle Aged; Multicenter Studies as Topic; Obesity; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult

2009
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Postgraduate medicine, 2010, Volume: 122, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biostatistics; Clinical Trials as Topic; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Epidemiologic Measurements; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones

2010
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
    Current opinion in psychiatry, 2011, Volume: 24, Issue:1

    Topics: Adult; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Sulpiride

2011
Therapeutic potential of new second generation antipsychotics for major depressive disorder.
    Expert opinion on investigational drugs, 2010, Volume: 19, Issue:12

    Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic

2010
Second-generation antipsychotics for major depressive disorder and dysthymia.
    The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12

    Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dysthymic Disorder; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Sulpiride

2010
Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.
    Journal of affective disorders, 2011, Volume: 128 Suppl 1

    Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Anxiety Disorders; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Mental Disorders; Piperazines; Quinolones

2011
Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder.
    Journal of affective disorders, 2011, Volume: 128 Suppl 1

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome

2011
Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.
    CNS drugs, 2011, Volume: 25, Issue:2

    Topics: Animals; Aripiprazole; Clinical Trials as Topic; Depressive Disorder, Major; Drug Interactions; Humans; Piperazines; Quinolones

2011
Lycanthropy as a culture-bound syndrome: a case report and review of the literature.
    Journal of psychiatric practice, 2012, Volume: 18, Issue:1

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior Control; Citalopram; Cultural Characteristics; Culture; Delusions; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Ethnopsychology; Female; Humans; Lebanon; Middle Aged; Mythology; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2012
Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
    International clinical psychopharmacology, 2012, Volume: 27, Issue:3

    Topics: Adult; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome

2012
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
    Acta psychiatrica Scandinavica, 2008, Volume: 117, Issue:4

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles

2008

Trials

48 trial(s) available for carbostyril and Depressive Disorder, Major

ArticleYear
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies.
    Journal of affective disorders, 2022, 11-01, Volume: 316

    Topics: Adult; Anhedonia; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Fatigue; Humans; Quinolones; Syndrome; Thiophenes; Treatment Outcome

2022
Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.
    The Journal of clinical psychiatry, 2019, 10-01, Volume: 80, Issue:6

    Topics: Adult; Antidepressive Agents; Blood Glucose; Body Weight; Cholesterol; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Middle Aged; Quinolones; Thiophenes; Triglycerides

2019
Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia.
    Journal of clinical pharmacology, 2018, Volume: 58, Issue:1

    Topics: Antipsychotic Agents; Area Under Curve; Asian People; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes

2018
Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
    Journal of affective disorders, 2018, Volume: 227

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Serotonin Agents; Thiophenes; Treatment Outcome

2018
A case study in identifying targeted patients population in major depressive disorder by enhanced enrichment design.
    Pharmaceutical statistics, 2018, Volume: 17, Issue:2

    Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Delivery Systems; Humans; Patient Selection; Quinolones; Serotonin Agents; Thiophenes; Treatment Outcome

2018
Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
    Current medical research and opinion, 2018, Volume: 34, Issue:4

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Headache; Humans; Male; Middle Aged; Prospective Studies; Psychomotor Agitation; Quetiapine Fumarate; Quinolones; Thiophenes; Treatment Outcome

2018
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
    The Journal of clinical psychiatry, 2018, 05-22, Volume: 79, Issue:4

    Topics: Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Psychiatric Status Rating Scales; Quinolones; Thiophenes; Treatment Outcome; Young Adult

2018
A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
    Acta neuropsychiatrica, 2019, Volume: 31, Issue:1

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Quinolones; Serotonin Agents; Thiophenes; Young Adult

2019
Dynamic prediction of treatment response in late-life depression.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2014, Volume: 22, Issue:2

    Topics: Age of Onset; Aged; Aged, 80 and over; Aripiprazole; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Remission Induction; Severity of Illness Index; Signal Detection, Psychological; Symptom Assessment; Treatment Outcome; Venlafaxine Hydrochloride

2014
The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
    International clinical psychopharmacology, 2013, Volume: 28, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Hostility; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Young Adult

2013
Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.
    International clinical psychopharmacology, 2013, Volume: 28, Issue:6

    Topics: Adult; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Secondary Prevention; Treatment Outcome

2013
Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
    Journal of affective disorders, 2013, Volume: 151, Issue:3

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Asian People; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Time Factors; Treatment Outcome

2013
Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting.
    International clinical psychopharmacology, 2014, Volume: 29, Issue:2

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome

2014
Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study.
    Journal of psychiatric research, 2014, Volume: 49

    Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Substitution; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones

2014
Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.
    Psychiatry research, 2014, Mar-30, Volume: 221, Issue:3

    Topics: Adult; Animals; Antidepressive Agents; Aripiprazole; Caudate Nucleus; Citalopram; Corpus Striatum; Depressive Disorder, Major; Dihydroxyphenylalanine; Dopamine; Dopamine Agonists; Drug Synergism; Female; Humans; Magnetic Resonance Imaging; Male; Piperazines; Positron-Emission Tomography; Quinolones; Sample Size; Single-Blind Method; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

2014
Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
    Journal of affective disorders, 2014, Volume: 162

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Odds Ratio; Piperazines; Psychomotor Agitation; Quinolones; Severity of Illness Index

2014
Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter
    Psychiatry and clinical neurosciences, 2015, Volume: 69, Issue:1

    Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index

2015
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    BMC research notes, 2014, Jul-18, Volume: 7

    Topics: Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Norepinephrine; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior; Treatment Outcome

2014
Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults.
    Pharmacopsychiatry, 2015, Volume: 48, Issue:4-5

    Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Benzhydryl Compounds; Cytochrome P-450 CYP3A Inducers; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; Humans; Male; Middle Aged; Modafinil; Piperazines; Quinolones; Wakefulness-Promoting Agents; Young Adult

2015
Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    The Journal of clinical psychiatry, 2015, Volume: 76, Issue:9

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Thiophenes; Treatment Outcome; Young Adult

2015
Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    The Journal of clinical psychiatry, 2015, Volume: 76, Issue:9

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Thiophenes; Treatment Outcome; Young Adult

2015
Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
    Journal of affective disorders, 2016, Sep-01, Volume: 201

    Topics: Adult; Antidepressive Agents; Anxiety Disorders; Depression; Depressive Disorder, Major; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psychomotor Agitation; Quinolones; Serotonin Agents; Thiophenes; Treatment Outcome

2016
Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
    Journal of affective disorders, 2016, Nov-01, Volume: 204

    Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Employment; Female; Follow-Up Studies; Humans; Male; Psychiatric Status Rating Scales; Quinolones; Students; Thiophenes; Treatment Outcome; Young Adult

2016
Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    The Journal of clinical psychiatry, 2016, Volume: 77, Issue:12

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irritable Mood; Male; Middle Aged; Outcome Assessment, Health Care; Quinolones; Serotonin Agents; Thiophenes

2016
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
    Brain and behavior, 2016, Volume: 6, Issue:10

    Topics: Anxiety; Depressive Disorder, Major; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Psychiatric Status Rating Scales; Psychotropic Drugs; Quinolones; Serotonin Agents; Thiophenes; Treatment Outcome

2016
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    The international journal of neuropsychopharmacology, 2017, 01-01, Volume: 20, Issue:1

    Topics: Antidepressive Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Impulsive Behavior; Male; Middle Aged; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Sleep; Thiophenes; Treatment Outcome

2017
Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
    The primary care companion for CNS disorders, 2016, Sep-08, Volume: 18, Issue:5

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Serotonin Agents; Sleep Wake Disorders; Thiophenes; Treatment Outcome

2016
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Quinolones; Sertraline; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult

2010
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:12

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Body Weight; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Quinolones; Treatment Outcome

2008
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:2

    Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Feasibility Studies; Female; Humans; Male; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Thiophenes; Venlafaxine Hydrochloride

2009
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
    Journal of psychiatric practice, 2009, Volume: 15, Issue:2

    Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome

2009
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    CNS spectrums, 2009, Volume: 14, Issue:4

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Endpoint Determination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Failure; Young Adult

2009
Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.
    Journal of affective disorders, 2010, Volume: 120, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Venlafaxine Hydrochloride

2010
A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:3

    Topics: Adolescent; Adult; Aged; Aripiprazole; Cross-Sectional Studies; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Physician's Role; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Young Adult

2010
Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:4

    Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Suicidal Ideation; Time Factors; Young Adult

2011
Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
    International journal of geriatric psychiatry, 2011, Volume: 26, Issue:6

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Young Adult

2011
The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2010, Volume: 93 Suppl 6

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Asian People; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Costs; Drug Therapy, Combination; Humans; Models, Economic; Outpatients; Piperazines; Quality-Adjusted Life Years; Quinolones; Thailand; Treatment Outcome

2010
Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012, Volume: 22, Issue:2

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clomipramine; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult

2012
Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:5

    Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline; Treatment Outcome; Young Adult

2011
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:3

    Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones

2012
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
    Psychotherapy and psychosomatics, 2012, Volume: 81, Issue:2

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Constipation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Placebos; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; United States; Weight Gain; Young Adult

2012
Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.
    Journal of psychopharmacology (Oxford, England), 2013, Volume: 27, Issue:3

    Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Functional Neuroimaging; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurons; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors

2013
Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:10

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome

2005
Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2007, Volume: 8, Issue:2

    Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Neurologic Examination; Personality Inventory; Piperazines; Quinolones

2007
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:6

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Severity of Illness Index; Treatment Outcome

2007
Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Endpoint Determination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones

2008
A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
    Journal of affective disorders, 2008, Volume: 110, Issue:1-2

    Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Lorazepam; Male; Middle Aged; Nausea; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome

2008
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment

2008

Other Studies

72 other study(ies) available for carbostyril and Depressive Disorder, Major

ArticleYear
Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial.
    BMJ open, 2022, 09-06, Volume: 12, Issue:9

    Topics: Adolescent; Depressive Disorder, Major; Humans; Quinolones; Sleep; Sleep Wake Disorders; Thiophenes; Young Adult

2022
Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures.
    Journal of biopharmaceutical statistics, 2020, 07-03, Volume: 30, Issue:4

    Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Computer Simulation; Data Interpretation, Statistical; Depressive Disorder, Major; Dose-Response Relationship, Drug; Endpoint Determination; Humans; Models, Statistical; Quinolones; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Treatment Outcome

2020
Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy.
    Journal of affective disorders, 2021, 01-01, Volume: 278

    Topics: Circadian Rhythm; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Melatonin; Quinolones; Sleep; Thiophenes; Treatment Outcome

2021
Interest-Activity Dimension and Response to Aripiprazole.
    The Journal of clinical psychiatry, 2020, 12-08, Volume: 82, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Humans; Quinolones

2020
Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.
    Psychopharmacology, 2017, Volume: 234, Issue:21

    Topics: Administration, Oral; Amino Acids; Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Fluoxetine; Ketamine; Male; Mice; Mice, Inbred C57BL; Quinolones; Receptors, N-Methyl-D-Aspartate; Thiophenes

2017
The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.
    Perspectives in psychiatric care, 2018, Volume: 54, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; New York; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Thiophenes; Treatment Outcome; Young Adult

2018
Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Journal of medical economics, 2018, Volume: 21, Issue:9

    Topics: Adult; Age Factors; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Expenditures; Health Resources; Health Services; Humans; Insurance Claim Review; Lurasidone Hydrochloride; Male; Middle Aged; Models, Econometric; Quetiapine Fumarate; Quinolones; Residence Characteristics; Retrospective Studies; Sex Factors; Socioeconomic Factors; Thiophenes; Time-to-Treatment

2018
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
    International clinical psychopharmacology, 2018, Volume: 33, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain

2018
Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.
    International journal of geriatric psychiatry, 2018, Volume: 33, Issue:10

    Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antidepressive Agents; Chemotherapy, Adjuvant; Depressive Disorder, Major; Europe; Fatigue; Female; Humans; Male; Quality of Life; Quinolones; Social Participation; Thiophenes; United States

2018
Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Clinical therapeutics, 2019, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Emergency Service, Hospital; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Medication Adherence; Middle Aged; Patient Acceptance of Health Care; Quetiapine Fumarate; Quinolones; Thiophenes; United States; Young Adult

2019
A pilot study of brexpiprazole for bipolar depression.
    Journal of affective disorders, 2019, Apr-15, Volume: 249

    Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cognition; Depressive Disorder, Major; Female; Humans; Irritable Mood; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Quinolones; Thiophenes; Treatment Outcome; Young Adult

2019
Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning.
    The Journal of clinical psychiatry, 2019, 04-30, Volume: 80, Issue:3

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Arousal; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Drug Approval; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Practice Patterns, Physicians'; Quality of Life; Quetiapine Fumarate; Quinolones; Sleep Initiation and Maintenance Disorders; Thiophenes

2019
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysfunction; Cyclohexanols; Dementia; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride

2014
Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
    CNS spectrums, 2014, Volume: 19, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Time Factors

2014
An aripiprazole discontinuation syndrome.
    Rhode Island medical journal (2013), 2013, Volume: 96, Issue:2

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome

2013
[Antipsychotics -- do they exist?].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2014, Volume: 16, Issue:2

    Topics: Adaptation, Psychological; Affect; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Corpus Striatum; Depressive Disorder, Major; Dopamine; Dopamine Agents; Humans; Obsessive-Compulsive Disorder; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Stress, Psychological; Thinking

2014
Aripiprazole augmentation of antidepressants for postpartum depression: a preliminary report.
    Archives of women's mental health, 2015, Volume: 18, Issue:1

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depression, Postpartum; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome

2015
How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine.
    Human psychopharmacology, 2014, Volume: 29, Issue:6

    Topics: Adult; Antidepressive Agents; Anxiety; Aripiprazole; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Precision Medicine; Prognosis; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Self Report; Treatment Outcome

2014
Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:9

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dibenzothiazepines; Drug Synergism; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hospitalization; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Taiwan; Treatment Outcome

2014
Brexpiprazole: another multipurpose antipsychotic drug?
    Journal of psychosocial nursing and mental health services, 2015, Volume: 53, Issue:4

    Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Humans; Psychomotor Agitation; Quinolones; Schizophrenia; Stress Disorders, Post-Traumatic; Thiophenes

2015
Efficacy of aripiprazole in antidepressants-induced tardive dystonia and tardive dyskinesia: a case report.
    Psychiatria Danubina, 2015, Volume: 27, Issue:2

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Middle Aged; Piperazines; Quinolones; Treatment Outcome

2015
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
    International journal of clinical practice, 2015, Volume: 69, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Thiophenes

2015
Mechanism of action of brexpiprazole: comparison with aripiprazole.
    CNS spectrums, 2016, Volume: 21, Issue:1

    Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Thiophenes

2016
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
    Journal of affective disorders, 2017, Jan-01, Volume: 207

    Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Depressive Disorder, Major; Disorders of Excessive Somnolence; Drug Costs; Drug Therapy, Combination; Fatigue; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Olanzapine; Patient Selection; Quetiapine Fumarate; Quinolones; Serotonin Agents; Thiophenes; Weight Gain; Young Adult

2017
Adjunctive brexpiprazole for the treatment of major depressive disorder.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:17

    Topics: Antidepressive Agents; Antipsychotic Agents; Chemotherapy, Adjuvant; Depressive Disorder, Major; Dopamine; Humans; Quinolones; Randomized Controlled Trials as Topic; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT1; Serotonin 5-HT1 Receptor Agonists; Thiophenes; Treatment Outcome

2016
Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling.
    Scientific reports, 2016, 12-19, Volume: 6

    Topics: Animals; Antidepressive Agents; Azepines; Behavior, Animal; Benzamides; Brain-Derived Neurotrophic Factor; Dendritic Spines; Depressive Disorder, Major; Disease Models, Animal; Drug Therapy, Combination; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Phenotype; Quinolones; Receptor, trkB; Selective Serotonin Reuptake Inhibitors; Signal Transduction; Thiophenes

2016
Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:2

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Irritable Mood; Middle Aged; Quinolones; Thiophenes

2017
The safety of the electroconvulsive therapy-aripiprazole combination: four case reports.
    The journal of ECT, 2008, Volume: 24, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Inpatients; Middle Aged; Piperazines; Quinolones; Safety; Schizophrenia

2008
Predictors of aripiprazole treatment continuation in hospitalized patients.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Cohort Studies; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Patient Discharge; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Treatment Outcome

2008
An open study of aripiprazole and escitalopram for psychotic major depressive disorder.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Selective Serotonin Reuptake Inhibitors

2009
Aripiprazole in refractory depression?
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:1

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome

2009
Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:1

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome

2009
Psychosis in the elderly.
    The American journal of psychiatry, 2009, Volume: 166, Issue:2

    Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Comorbidity; Cyclohexanols; Delirium; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Memantine; Nootropic Agents; Piperazines; Psychotherapy; Psychotic Disorders; Quinolones; Risk Factors; Treatment Outcome; Venlafaxine Hydrochloride

2009
Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
    International clinical psychopharmacology, 2009, Volume: 24, Issue:3

    Topics: Adult; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Data Interpretation, Statistical; Depressive Disorder, Major; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Socioeconomic Factors; Treatment Failure

2009
Potential utility of aripiprazole monotherapy for the treatment of major depressive disorder comorbid with obsessive-compulsive disorder.
    Psychiatry and clinical neurosciences, 2009, Volume: 63, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Treatment Outcome

2009
Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
    Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:10

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome

2009
Aripiprazole, hypertension, and confusion.
    The Journal of neuropsychiatry and clinical neurosciences, 2010,Winter, Volume: 22, Issue:1

    Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Confusion; Depressive Disorder, Major; Female; Humans; Hypertension; Piperazines; Quinolones

2010
[Difficulties in changing drugs--from clozapine to aripiprazole in ambulatory care].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2010, Volume: 12, Issue:1

    Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Clozapine; Depressive Disorder, Major; Drug Administration Schedule; Humans; Interpersonal Relations; Male; Middle Aged; Obesity; Patient Education as Topic; Patient Satisfaction; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Spouses

2010
Aripiprazole-induced gray matter growth in a patient with major depressive disorder with panic disorder.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Comorbidity; Depressive Disorder, Major; Female; Humans; Magnetic Resonance Imaging; Organ Size; Panic Disorder; Piperazines; Quinolones; Receptors, Serotonin

2010
Aripiprazole monotherapy in a patient with major depressive disorder.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Aug-16, Volume: 34, Issue:6

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Piperazines; Quinolones; Treatment Outcome

2010
[Use of aripiprazole in the treatment of catatonia].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2010, Volume: 12, Issue:2

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Depressive Disorder, Major; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Performance; Quinolones; Schizoid Personality Disorder; Schizophrenia, Catatonic

2010
Aripiprazole-related subcortical growth in a patient with major depressive disorder and panic disorder.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Depressive Disorder, Major; Humans; Male; Panic Disorder; Piperazines; Quinolones; Treatment Outcome

2010
Aripiprazole augmentation induced hypertension in major depressive disorder: a case report.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jan-15, Volume: 35, Issue:1

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Synergism; Duloxetine Hydrochloride; Female; Humans; Hypertension; Middle Aged; Piperazines; Quinolones; Thiophenes

2011
New-onset psychosis and emergence of suicidal ideation with aripiprazole.
    The American journal of psychiatry, 2010, Volume: 167, Issue:12

    Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Middle Aged; Piperazines; Psychoses, Substance-Induced; Quinolones; Suicidal Ideation

2010
Three cases of hypomania and one case of mania during aripiprazole treatment.
    Pharmacopsychiatry, 2011, Volume: 44, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Young Adult

2011
Aripiprazole adjunctive to antidepressant therapy.
    The American journal of psychiatry, 2011, Volume: 168, Issue:2

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones

2011
Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review.
    BMC psychiatry, 2011, May-17, Volume: 11

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotropic Drugs; Quinolones; Retrospective Studies; Stress Disorders, Post-Traumatic; Veterans

2011
Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
    Clinical therapeutics, 2011, Volume: 33, Issue:9

    Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Databases, Factual; Depressive Disorder, Major; Dibenzothiazepines; Drug Costs; Drug Therapy, Combination; Drug Utilization Review; Female; Health Expenditures; Humans; Insurance Claim Review; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Young Adult

2011
Adjunctive antipsychotics for major depression.
    The Medical letter on drugs and therapeutics, 2011, Sep-19, Volume: 53, Issue:1373

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Approval; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; United States; United States Food and Drug Administration

2011
Comparison of academic and nonacademic sites in multi-center clinical trials.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:1

    Topics: Academic Medical Centers; Academies and Institutes; Adult; Antipsychotic Agents; Aripiprazole; Boston; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Hospitals, General; Humans; Interview, Psychological; Male; Middle Aged; Multicenter Studies as Topic; Patient Dropouts; Patient Selection; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Young Adult

2012
The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cross-Cultural Comparison; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Thailand; Young Adult

2012
Adjunctive aripiprazole for depression: predictive value of early assessment.
    The American journal of managed care, 2011, Volume: 17, Issue:12

    Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Health Status Indicators; Humans; Logistic Models; Models, Psychological; Multivariate Analysis; Piperazines; Predictive Value of Tests; Prospective Studies; Psychometrics; Quinolones; Time Factors

2011
Nowhere patients.
    Psychotherapy and psychosomatics, 2012, Volume: 81, Issue:2

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Male; Models, Statistical; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors

2012
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:5

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Costs; Drug Resistance; Fluoxetine; Health Care Costs; Humans; Piperazines; Quetiapine Fumarate; Quinolones

2012
Aripiprazole monotherapy-related gray-matter growth in a patient with first-episode drug-naïve non-psychotic major depressive disorder.
    The Journal of neuropsychiatry and clinical neurosciences, 2012,Summer, Volume: 24, Issue:3

    Topics: Aripiprazole; Brain; Depressive Disorder, Major; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Piperazines; Quinolones

2012
Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: dose-related phenomenon?
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:6

    Topics: Aripiprazole; Bipolar Disorder; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Piperazines; Quinolones; Recurrence

2012
Aripiprazole for the treatment of involuntary movement symptoms in patients with major depressive disorder.
    The Journal of neuropsychiatry and clinical neurosciences, 2012,Fall, Volume: 24, Issue:4

    Topics: Aripiprazole; Depressive Disorder, Major; Dyskinesias; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Treatment Outcome

2012
Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010).
    International clinical psychopharmacology, 2013, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cohort Studies; Depressive Disorder, Major; Dibenzothiazepines; Drug Approval; Drug Prescriptions; Drug Therapy, Combination; Drugs, Investigational; Female; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Retrospective Studies; Spatio-Temporal Analysis; United States; United States Food and Drug Administration; Young Adult

2013
A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.
    Statistics in medicine, 2013, Jul-20, Volume: 32, Issue:16

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Depressive Disorder, Major; Humans; Linear Models; Piperazines; Placebo Effect; Quinolones; Randomized Controlled Trials as Topic; Research Design

2013
Aripiprazole as an adjunctive treatment for refractory major depression.
    Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:8

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones

2004
Aripiprazole-induced seizure.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2005, Volume: 50, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Diagnosis, Differential; Epilepsy, Complex Partial; Humans; Male; Piperazines; Quinolones

2005
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
    Journal of psychiatric practice, 2005, Volume: 11, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome

2005
Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2005
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:10

    Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Research Design; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome

2005
Aripiprazole-induced parkinsonism.
    International clinical psychopharmacology, 2006, Volume: 21, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Male; Middle Aged; Parkinsonian Disorders; Piperazines; Quinolones

2006
Aripiprazole-related tardive dyskinesia.
    CNS spectrums, 2006, Volume: 11, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Quinolones

2006
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response.
    Depression and anxiety, 2007, Volume: 24, Issue:7

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2007
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.
    Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:2

    Topics: Adult; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones

2007
Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Middle Aged; Monoamine Oxidase Inhibitors; Piperazines; Quinolones; Tranylcypromine; Treatment Outcome

2007
Reversal of trichotillomania with aripiprazole.
    Depression and anxiety, 2008, Volume: 25, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Morpholines; Piperazines; Quinolones; Reboxetine; Self Concept; Sertraline; Social Adjustment; Trichotillomania

2008
A case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:10

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Ephedrine; Feeding and Eating Disorders; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders

2007
Effectiveness of aripiprazole in treating obsessive compulsive symptoms.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2008